Qcancer Scores
Download
Report
Transcript Qcancer Scores
+
New tools to support decisions and diagnoses
Julia Hippisley-Cox,
GP, Professor Epidemiology & Director ClinRisk Ltd
EMIS NUG 12
06 Sept 2012
+
Acknowledgements
Co-authors
QResearch database
EMIS & contributing practices & User Group
University of Nottingham
ClinRisk (software)
Oxford University (independent validation)
+
Outline
QSurveillance in EMIS Web
QResearch data linkage project/Openpseudonymiser
QFracture
QCancer
QDiabetes - Dr Tim Walter
Work in progress
Discussion
+
QSurveillance live in EMIS Web
Infectious diseases surveillance
to the HPA
Automated vaccine returns DH
QFeedback system
Available all LV and EMIS Web
For existing sites, check
activation EMAS manager
If new, then email
[email protected]
g
+
QSurveillance in Enquiry manager
+
QFeedback in LV
+
QFeedback for EMIS LV and Web
+
QResearch Database
Over 700 general practices across the UK, 14 million patients
Joint venture between EMIS and University of Nottingham
Patient level pseudonymised database for research
Available for peer reviewed academic research where
outputs made publically available
Open to all EMIS LV and Web practices including Scotland
Data linkage – deaths, deprivation, cancer, HES
+
QResearch Data Linkage Project
QResearch database already linked to
deprivation data
cause of death data
Very useful for research
better definition & capture of outcomes
Health inequality analysis
Improved performance of QRISK and similar scores
Planning additional linkages
HES
Cancer registries
+
New approach pseudonymisation
member of ECC of NIGB. s251 approvals for use of
identifiable data where public interest but consent not
possible and no practical alternative
Need approach which doesn’t extract identifiable data but
still allows linkage
Legal, ethical and NIGB approvals
Secure, Scalable
Reliable, Affordable
Generates ID which are Unique to Project
Applied within the heart of the clinical system
Minimise disclosure
+
www.openpseudonymiser.org
Scrambles NHS number BEFORE extraction from
clinical system
Takes NHS number + project specific encrypted ‘salt
code’
One way hashing algorithm (SHA2-256)
Cant be reversed engineered
Applied twice in to separate locations before data
leaves source
Apply identical software to external dataset
Allows two pseudonymised datasets to be linked
+
Open Pseudonymiser
Open P has been accepted as a standard by a number of major
organisations including
NIGB
EMIS NUG
EMIS & other GP suppliers
BMA
NHS Information Centre
Office National Statistics
EMIS is integrating it into so practices can ‘pseudonymised at
source’
This is the ‘practical alternative’ to using identifiable data when
consent is impossible and helps protect patient confidentiality.
“If in doubt, pseudonymise it!”
+
+
Get switched on
all LV and Web practices
welcome to contribute to
both QResearch &
QSurveillance
Email [email protected]
+
Clinical Research Cycle
Clinical
practice &
benefit
Integration
clinical
system
Clinical
questions
Research +
innovation
+
QScores – new family of Risk Prediction
tools
Individual assessment
Who is most at risk of preventable disease?
Who is likely to benefit from interventions?
What is the balance of risks and benefits for my patient?
Enable informed consent and shared decisions
Population level
Risk stratification
Identification of rank ordered list of patients for recall or reassurance
GP systems integration
Allow updates tool over time, audit of impact on services and
outcomes
+
Current published & validated
QScores
scores
outcome
Web link
QRISK
CVD
www.qrisk.org
QDiabetes
Type 2 diabetes
www.qdiabetes.org
QKidney
Moderate/severe renal failure
www.qkidney.org
QThrombosis
VTE
www.qthrombosis.org
QFracture
Osteoporotic fracture
www.qfracture.org
Qintervention
Risks benefits interventions to www.qintervention.org
lower CVD and diabetes risk
QCancer
Detection common cancers
www.qcancer.org
+
Today we will cover three tools
QFracture
QCancer
QDiabetes – Dr Tim Walters
+
QFracture: Background
Osteoporosis
major cause preventable morbidity &
mortality.
300,000
osteoporosis fractures each year
30%
women over 50 years will get vertebral fracture
20% hip fracture patients die within 6/12
50%
hip fracture patients lose the ability to live
independently
2
billion is cost of annual social and hospital care
21
+
QFracture: challenge
Effective
interventions exist to reduce fracture risk
Challenge
is better identification of high risk
patients likely to benefit
Avoid
over treatment in those unlikely to benefit or
who may be harmed
Some
guidelines recommend BMD but expensive
and not very specific
+
QFracture in national guidelines
Published August 2012
Assess fracture risk all women
65+ and all men 75+
Assess fracture risk if risk
factors
Estimate 10 year fracture risk
using QFracture or FRAX
Consider use of medication to
reduce fracture risk
+
Two new indicators recommended
QOF 2013 for Rheumatoid Arthritis
ID
indicator
Comments
NM56
% patients with RA 30-84 years
who have had a CVD risk
assessment using a CVD risk
assessment for RA in last 15/12
QRISK2 only CVD risk tool
- 30-84 yrs
- adjusted for RA
NM57
% of patients with RA 50-90yrs
NICE recommends QFracture
with rheumatoid arthritis who
have had fracture risk assessment
using tool adjusted for RA in last
27 months
http://www.nice.org.uk/media/D76/FE/NICEQOFAdvisoryCommittee2012SummayRecommendations.pdf
+ Comparison of QFracture vs FRAX
QFracture
Developed in UK primary care
Better identifies high risk
Less likely to over predict
Independent external validation
Risk over different time periods
Includes extra factors known to
affect fracture risk eg
Antidepressants
Nursing home
Falls
Will be integrated EMIS Web
FRAX
Mostly non-UK research cohorts
Industry sponsored
Over predicts leading to over
treatment
Lack of independent validation
Not published and open to
scrutiny
+ QFracture Web calculator
www.qfracture.org
•
•
•
•
•
•
•
•
Example:
64 year old women
History of falls
Asthma
Rheumatoid arthritis
On steroids
10% risk hip fracture
20% risk of any
fracture
+
QScores on the app store
+
Early diagnosis of cancer: The
problem
UK has relatively poor track record when compared with
other European countries
Partly due to late diagnosis with estimated 7,500+ lives lost
annually
Later diagnosis due to mixture of
late presentation by patient (alack awareness)
Late recognition by GP
Delays in secondary care
+
Symptoms based approach
Patients present with symptoms
GPs need to decide which patients to investigate and refer
Decision support tool must mirror setting where decisions made
Symptoms based approach needed (rather than cancer based)
Must account for multiple symptoms
Must have face clinical validity eg adjust for age, sex, smoking,
FH
updated to meet changing requirements, populations, recorded
data
+
QCancer scores – what they need
to do
Accurately predict level of risk for individual based on risk
factors and multiple symptoms
Discriminate between patients with and without cancer
Help guide decision on who to investigate or refer and
degree of urgency.
Educational tool for sharing information with patient.
Sometimes will be reassurance.
+
Methods – development algorithm
Huge representative sample from QResearch aged 30-84
Identify new alarm symptoms (eg rectal bleeding,
haemoptysis) and other risk factors (eg age, COPD, smoking,
family history)
Identify cancer outcome - all new diagnoses either on GP
record or linked ONS deaths record in next 2 years
Established methods to develop risk prediction algorithm
Identify independent factors adjusted for other factors
Measure of absolute risk of cancer. Eg 5% risk of colorectal
cancer
+
‘Red’ flag or alarm symptoms
(identified from studies including NICE guidelines 2005)
Haemoptysis
Loss of appetite
Haematemesis
Weight loss
Dysphagia
Indigestion +/- heart burn
Rectal bleeding
Abdominal pain
Vaginal bleeding
Abdominal swelling
Haematuria
Family history
Anaemia
Breast lump, pain, skin
tethering
dysphagia
Constipation, cough
+ Qcancer now predicts risk all
major cancers including
Lung
Pancreas
Colorectal
Gastro
Testis
Breast
Prostate
Blood
Kidney
Ovary
Cervix
Uterus
+ Results – the algorithms/predictors
Outcome
Risk factors
Symptoms
Lung
Age, sex, smoking,
deprivation, COPD,
prior cancers
Haemoptysis, appetite loss, weight loss,
cough, anaemia
Gastrooeso
Age, sex, smoking
status
Haematemsis, appetite loss, weight loss,
abdo pain, dysphagia
Colorectal Age, sex, alcohol,
family history
Rectal bleeding, appetite loss, weight loss,
abdo pain, change bowel habit, anaemia
Pancreas
Age, sex, type 2,
chronic pancreatitis
dysphagia, appetite loss, weight loss,
abdo pain, abdo distension, constipation
Ovarian
Age, family history
Rectal bleeding, appetite loss, weight loss,
abdo pain, abdo distension, PMB, anaemia
Renal
Age, sex, smoking
status, prior cancer
Haematuria, appetite loss, weight loss,
abdo pain, anaemia
+
Methods - validation is crucial
Essential to demonstrate the tools work and identify right
people in an efficient manner
Tested performance
separate sample of QResearch practices
external dataset (Vision practices) at Oxford University
Measures of discrimination - identifying those who do and
don’t have cancer
Measures of calibration - closeness of predicted risk to
observed risk
Measure performance – Positive predictive value, sensitivity
+
Using QCancer in practice – v similar
to QRISK2
Standalone tools
a.
Web calculator
www.qcancer.org/2013/female/php
www.qcancer.org/2013/male/php
b.
Windows desk top calculator
c.
Iphone – simple calculator
Integrated into clinical system
a.
Within consultation: GP with patients with symptoms
b.
Batch: Run in batch mode to risk stratify entire practice or
PCT population
+ QCancer – women
http://qcancer.org/2013/female/index.php
PROFILE
64yr old woman,
Moderate smoker
Loss appetite
Abdo pain
Abdo swelling
72% risk of no cancer
28% risk any cancer
- ovarian = 20%
- colorectal = 1.5%
- pancreas =.16%
- Other 3.4%
+ QCancer – men
http://qcancer.org/2013/male/index.php
PROFILE
• 64yr old man,
• Heavy smoker
• FH GI cancer
• Loss appetite
• Recent VTE
• Weight loss
• Indigestion
• RESULTS
• 71% risk of no
cancer
• 29% risk any cancer
• Lung = 9%
• Pancreas =6%
• Prostate =2%
• Other =5%
+
GP system integration:
Within consultation
Uses data already recorded (eg age, family history)
Use of alerts to prompt use of template
Automatic risk calculation in real time
Display risk enables shared decision making
Information stored in patients record and transmitted on
referral letter/request for investigation
Allows automatic subsequent audit of process and clinical
outcomes
+
GP systems integration
Batch processing
Similar to QRISK which is in 95% of GP practices– automatic
daily calculation of risk for all patients in practice based on
existing data.
Identify patients with symptoms/adverse risk profile without
follow up/diagnosis
Enables systematic recall or further investigation
Systematic approach - prioritise by level of risk.
+
Comparison other cancer risk
tools
QCancer
The “RAT”
Large UK sample with data
until 2012
30-40 Exeter practices; paper
records from 10 yrs ago
Symptoms based approach
Takes account of risk factors
including age, sex, smoking,
FH
Focused on single symptoms
and pairs where enough data
Independent external
validation by Oxford
university
Doesn’t adjust for age
although cancer risk clearly
changes with age
Not been validated
(independently or by authors)
Distributed as a mouse mat for
each cancer
Can be updated and
integrated into computer
systems into workflow
+ Next steps - pilot work in clinical
practice supported by DH
+
Work in progress; QAdmissions
New tool to identify patients at risk of emergency admission
“QAdmissions”
Based on pseudonymised linked primary and secondary care
data on QResearch
Will predict overall admission risk but also top most common
type of admission
cardiovascular
Asthma etc
So that interventions can be better targeted to prevent
admission
In partnership with East London. Hear more at Kambiz Boomla
session tomorrow
+
QDiabetes
Preventing type 2
diabetes - risk
identification &
interventions for
individuals at high risk
2012
• Type 2 diabetes epidemic
• Potential for prevention
• Risk assessment using validated
risk tools including QDiabetes
• Individual assessment and also
batch processing
• QDiabetes is UK & fully validated
• Includes deprivation & ethnicity
• Ages 25-84
• Efficient as 2 extra questions on top
of QRISK
• www.qintervention.org
• Already integrated into EMIS Web
• Evaluation in London and Berkshire
+
Thank you for listening
Questions & Discussion